WallStreetZenWallStreetZen

NASDAQ: DRMA
Dermata Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for DRMA

Based on 1 analyst offering 12 month price targets for Dermata Therapeutics Inc

Min Forecast
$10.00+170.27%
Avg Forecast
$10.00+170.27%
Max Forecast
$10.00+170.27%

Should I buy or sell DRMA stock?

Based on 1 analyst offering ratings for Dermata Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DRMA stock forecasts and price targets.

DRMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-21

1 of 1

Forecast return on equity

Is DRMA forecast to generate an efficient return?

Company
-77.14%
Industry
71.5%
Market
262.89%
DRMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DRMA forecast to generate an efficient return on assets?

Company
-65.22%
Industry
24.27%
DRMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DRMA earnings per share forecast

What is DRMA's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$7.92
Avg 2 year Forecast
-$6.35

DRMA revenue forecast

What is DRMA's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

DRMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DRMA$3.70$10.00+170.27%Strong Buy
SLXN$3.44N/AN/A
MLEC$0.62N/AN/A
ELAB$5.84N/AN/A
XRTX$0.65N/AN/A
View Top Biotech Stocks

Dermata Therapeutics Stock Forecast FAQ

Is Dermata Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DRMA) stock is to Strong Buy DRMA stock.

Out of 1 analyst, 1 (100%) are recommending DRMA as a Strong Buy, 0 (0%) are recommending DRMA as a Buy, 0 (0%) are recommending DRMA as a Hold, 0 (0%) are recommending DRMA as a Sell, and 0 (0%) are recommending DRMA as a Strong Sell.

If you're new to stock investing, here's how to buy Dermata Therapeutics stock.

What is DRMA's earnings growth forecast for 2025-2026?

(NASDAQ: DRMA) Dermata Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 119.69%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,754.17%.

Dermata Therapeutics's earnings in 2025 is -$10,328,774.On average, 3 Wall Street analysts forecast DRMA's earnings for 2025 to be -$5,394,660, with the lowest DRMA earnings forecast at -$5,183,105, and the highest DRMA earnings forecast at -$5,553,326.

In 2026, DRMA is forecast to generate -$4,331,022 in earnings, with the lowest earnings forecast at -$4,161,178 and the highest earnings forecast at -$4,458,405.

What is DRMA's revenue growth forecast for 2025-2026?

(NASDAQ: DRMA) Dermata Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 9,181.71%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,351.27%.

Dermata Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast DRMA's revenue for 2025 to be $0, with the lowest DRMA revenue forecast at $0, and the highest DRMA revenue forecast at $0.

In 2026, DRMA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is DRMA's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: DRMA) forecast ROA is -65.22%, which is lower than the forecast US Biotechnology industry average of 24.27%.

What is DRMA's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DRMA price target, the average DRMA price target is $10.00, with the highest DRMA stock price forecast at $10.00 and the lowest DRMA stock price forecast at $10.00.

The Wall Street analyst predicted that Dermata Therapeutics's share price could reach $10.00 by Aug 21, 2026. The average Dermata Therapeutics stock price prediction forecasts a potential upside of 170.27% from the current DRMA share price of $3.70.

What is DRMA's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: DRMA) Dermata Therapeutics's current Earnings Per Share (EPS) is -$4.66. On average, analysts forecast that DRMA's EPS will be -$7.92 for 2025, with the lowest EPS forecast at -$7.60, and the highest EPS forecast at -$8.15. In 2026, DRMA's EPS is forecast to hit -$6.35 (min: -$6.11, max: -$6.54).

What is DRMA's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: DRMA) forecast ROE is -77.14%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.